Michael Gibney

Michael Gibney
Michael Gibney

Michael Gibney is a former editor at FierceMarkets Life Sciences group.

Stories by Michael Gibney

Nasdaq screens

FDA delivery-based withdrawal has Lannett, Mallinckrodt flailing

Generics of Johnson & Johnson’s ADHD pill Concerta are hitting hard times due to an FDA crackdown on their bioequivalence. The agency said six months ago that generics makers Lannett and Mallinckrodt had that much time to confirm their extended-release technology matched that of J&J’s.

Nanoparticles alone form 'wave of destruction' against cancer cells

Cornell Professor Ulrich Wiesner’s C-dots are showing more and more that they could be the next big step in nanotech drug delivery. In their latest incarnation, the diagnostic and delivery combination particles have shown that they can alone deprive cancer cells of nutrients, resulting in their death.